Comments on: Will the Vise Tighten on Pay-for-Delay Agreements? http://blog.pharmtech.com/2011/01/17/will-the-vise-tighten-on-pay-for-delay-agreements/ The blog of Pharmaceutical Technology magazine Thu, 09 May 2013 23:30:55 -0400 http://wordpress.org/?v=2.8.4 hourly 1 By: cliffintokyo http://blog.pharmtech.com/2011/01/17/will-the-vise-tighten-on-pay-for-delay-agreements/comment-page-1/#comment-34644 cliffintokyo Mon, 24 Jan 2011 07:30:31 +0000 http://blog.pharmtech.com/?p=3810#comment-34644 Every company (not only pharma) fears competition. The question is, what to do about it. From a business viewpoint, "only inaction is a crime", to quote a well known entrepreneur. Every company (not only pharma) fears competition.
The question is, what to do about it.
From a business viewpoint, “only inaction is a crime”, to quote a well known entrepreneur.

]]> By: Girish Malhotra http://blog.pharmtech.com/2011/01/17/will-the-vise-tighten-on-pay-for-delay-agreements/comment-page-1/#comment-34588 Girish Malhotra Fri, 21 Jan 2011 18:21:49 +0000 http://blog.pharmtech.com/?p=3810#comment-34588 Interesting thought process for Sanofi. Barr and Watson may be selling the drug but the active pharmaceutical ingredient was being manufactured by others in India. Another secret. Many drug companies do want the dealings with generics to come out. In the last 24 hours the following appeared. "Pfizer Inc., Merck & Co. and 35 other pharmaceutical companies have asked a federal judge to block the release of confidential documents detailing drug-patent litigation settlements, which Cephalon Inc. has requested as part of an antitrust dispute with the government." http://online.wsj.com/article/SB10001424052748704881304576094192652807246.html?KEYWORDS=cephalon Actually there is an alternate strategy but that will impact the current business model. That can make things challenging for many involved on both sides of the fence. Life will go on. Interesting thought process for Sanofi.

Barr and Watson may be selling the drug but the active pharmaceutical ingredient was being manufactured by others in India. Another secret.

Many drug companies do want the dealings with generics to come out. In the last 24 hours the following appeared.

“Pfizer Inc., Merck & Co. and 35 other pharmaceutical companies have asked a federal judge to block the release of confidential documents detailing drug-patent litigation settlements, which Cephalon Inc. has requested as part of an antitrust dispute with the government.”

http://online.wsj.com/article/SB10001424052748704881304576094192652807246.html?KEYWORDS=cephalon

Actually there is an alternate strategy but that will impact the current business model. That can make things challenging for many involved on both sides of the fence. Life will go on.

]]>